SARS-CoV-2-neutralising antibody BGB-DXP593 in mild-to-moderate COVID-19: a multicentre, randomised, double-blind, phase 2 trialResearch in context

SARS-CoV-2-neutralising antibody BGB-DXP593 in mild-to-moderate COVID-19: a multicentre, randomised, double-blind, phase 2 trialResearch in context

Summary: Background: BGB-DXP593, a neutralising monoclonal antibody against SARS-CoV-2, has demonstrated strong activity in reducing viral RNA copy number in SARS-CoV-2-infected animal models. We aimed to examine the efficacy and safety of BGB-DXP593 in ambulatory patients with mild-to-moderate COV...

Full description

Bibliographic Details
Main Authors: Ramses Vega, Martti Antila, Carlos Perez, Mohamed Mookadam, Fangjie Xie, Wei Zhang, Ahsan Rizwan, Zhen Yao, John E.J. Rasko
Format: Article
Language:English
Published: Elsevier 2023-03-01
Series:EClinicalMedicine
Subjects:
SARS-CoV-2
Neutralising monoclonal antibody
BGB-DXP593
Viral load or viral RNA copy number
COVID-19
Phase 2 trial
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537023000093

Internet

http://www.sciencedirect.com/science/article/pii/S2589537023000093

Similar Items